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Aims Human influenza A virus (hIAV) infection is associated with important cardiovascular complications, although car-
diac infection pathophysiology is poorly understood. We aimed to study the ability of hIAV of different pathogenic-
ity to infect the mouse heart, and establish the relationship between the infective capacity and the associated in vivo,




We evaluated lung and heart viral titres in mice infected with either one of several hIAV strains inoculated intranasally. 3D
reconstructions of infected cardiac tissue were used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells,
and cardiac vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced pluripotent stem
cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection and study underlying molecular alterations asso-
ciated with the in vivo electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and replicated in car-
diomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also present in cardiac endothelial cells. Remarkably, lung vi-
ral titres did not statistically correlate with viral titres in the mouse heart. The highly pathogenic human recombinant virus
PAmut showed faster replication, higher level of inflammatory cytokines in cardiac tissue and higher viral titres in cardiac
HL-1 mouse cells and hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction altera-
tions were especially pronounced in PAmut-infected mice, associated with high mortality rates, compared with PB2mut-
infected animals. Consistently, connexin43 and NaV1.5 expression decreased acutely in hiPSC-CMs infected with PAmut vi-
rus. YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected hiPSC-CMs compared with
PB2mut-infected cells, consistent with mitochondrial dysfunction. Human IAV infection did not increase myocardial fibrosis
at 4-day post-infection, although PAmut-infected mice showed an early increase in mRNAs expression of lysyl oxidase.
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Conclusion Human IAV can infect the heart and cardiac-specific conduction system, which may contribute to cardiac complica-
tions and premature death.
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1. Introduction
The influenza A virus (IAV) is a major contributor to acute respira-
tory infections,1 but its pathogenicity is not limited to respiratory
damage. Various complications in non-respiratory tissues (e.g. enceph-
alopathy) have been described during seasonal influenza infections,2,3
Among others, myocarditis and congestive heart failure have been as-
sociated with IAV infection,4–9 Focal-to-diffuse myocarditis has been
reported during the Asian and 1918 influenza pandemics.10 More re-
cently, during the 2009 pandemic, cardiac complications have been
described in 4.9% of hospitalized patients, and up to 46% of patients
admitted to intensive care units.11 Current evidence also indicates
that, in patients with pre-existing atherosclerotic disease, pulmonary
infection induces an inflammatory response that may trigger an acute
coronary syndrome.12 Moreover, severe ventricular arrhythmia with
fatal consequences and high-degree atrio-ventricular block have been
also reported in infected patients, even without apparent respiratory
damage.13,14
Despite potential IAV-related cardiac damage after infection, the rare
reports showing viral material in the human myocardium remain uncon-
firmed.15 Moreover, human IAV pathophysiology in cardiac tissue and
the associated in vivo, cellular and molecular alterations remain unex-
plored. Thus, current understanding mostly assumes that cardiac
pathology on human IAV infection is directly related to respiratory tract
damage and a subsequent inflammatory reaction that may lead to cardiac
complications in patients with significant comorbidities.12,16
Importantly, during the process of identifying the pathogenicity fac-
tor of a lethal influenza A virus (F-IAV) isolated from the 2009 pan-
demic,17 we generated recombinant viruses carrying mutations in PA
and PB2 viral polymerase subunits of F-IAV on the A/H1N1/
California/04/09 virus backbone (CAL).17 The use of a recombinant
virus carrying PA D529N (PAmut) showed that this mutation was re-
sponsible for the augmented pathogenicity of the F-IAV isolate, while
a recombinant virus with the mutation PB2 A221T (PB2mut) was at-
tenuated in mice.17 Here, we hypothesize that human IAV can also
infect and replicate in the mouse heart and cultured cardiomyocytes.
Moreover, cardiac damage and underlying molecular alterations will
be directly associated with virus pathogenicity, although cardiac infec-
tion and viral titres in heart tissue will not necessarily follow a direct
relationship with lung titres. We tested this hypothesis using patho-
genic PAmut and attenuated PB2mut recombinant viruses to explore
the ability of human IAV to infect and trigger cardiac damage in
infected mice in vivo, heart tissue samples and cultured cardiomyo-
cytes. We also studied the underlying molecular alterations associ-
ated with the in vivo virus-related electrophysiological phenotype
using infected human-induced pluripotent stem cell-derived








































































































cardiomyocytes (hiPSC-CMs). Altogether, our data report direct car-
diac infection and heart damage related to human IAV pathogenicity
and not necessarily related to lung viral titres, which may contribute
to the severity or even fatality of influenza virus infections in humans.
2. Methods
The in vivo studies were conducted in accordance with institutional
guidelines and National, European, and US National Institute of
Health guidelines for the care and use of laboratory animals.
Protocols were approved by the National Center for Biotechnology
Ethics Committee on Animal Experimentation (permit no. 11014)
and Institutional Animal Care and Use Committee of the University
of Michigan (approval no. PRO0006827). Animals were anesthetized
with isoflurane (3%) in an inhalation chamber before viral inoculation.
Animals were euthanized with isoflurane (7%) inhalation followed by
a second euthanasia method (bilateral pneumothorax or removal of
vital organs, lungs and/or heart as indicated). Figure 1 shows a flow-
chart with all the experimental sets.
2.1 Biological materials
Cell lines used in this study were MDCK (canine kidney; ATCC CCL-
34), and cardiac HL-1 (mouse). Human-induced PSC-CMs were derived
from iCellTM cardiomyocytes obtained from Cellular Dynamics
International (Madison, WI) using a modified protocol previously de-
scribed elsewhere18 (more details in Supplementary material online).
Briefly, the iCellTM cardiomyocytes were thawed and plated in differenti-
ation medium (EB20), and 24 h later, medium was switched to RPMI plus
B27 supplement with insulin (Gibco). Antibodies to GAPDH, b-actin
(both from Sigma), and rabbit anti-NP–PB1 antibodies were used for
western blot.19,20 Western-blot assays were performed as described
elsewhere.21
2.2 Cell infection
Cultured mouse HL-1 cells were infected at 10-3 or 3–5 plaque-forming
units (pfu)/cell as indicated in each experiment. Cells were used for
western-blot and immunofluorescence analyses, and supernatants were
used for virus titration by standard plaque assay.22 Human iPSC-CM cul-
tures were Mock-infected or infected with PAmut or PB2mut recombi-
nants at 3 multiplicity of infection (moi).
2.3 Mice with Connexin40 and
green-fluorescent protein (Cx40eGFP)
We used Cx40eGFP mice to enable visualization of the Purkinje network
via GFP expression. Founders for our Cx40eGFP mouse colony were
generously provided by the laboratory of Dr Daniel Gros at Université
de la Méditerranée, Marseille, France. Generation and characterization
of these transgenic mice have been described in detail previously.23
Briefly, these mice were generated by insertion of the eGFP coding se-
quence into the GJA5 gene locus by homologous recombination, and
were maintained under a mixed genetic background (CD1/129 Sv).
Heterozygous offspring were intercrossed to obtain homozygously mu-
tated progeny, as described elsewhere.23
2.4 In vivo virus infections in mice
All animal studies were performed under biosafety level 2þ conditions.
Female BALB/c AnNHsd mice (6 weeks old) were infected intranasally
with the corresponding recombinant viruses at 106 or 103 plaque-
forming units (pfu) as indicated in each experiment or were Mock-
infected. Female Cx40eGFP mice (7 weeks old) were also infected intra-
nasally with PAmut or PB2mut viruses at 106 pfu, or were Mock-
infected. All animals were monitored daily for body weight. For ethical
reasons, in all experiments, mice were euthanized when a 25% body
weight loss was documented. Total heart or lung extracts were used for
viral titre determination by plaque assay, biochemical analysis, or confo-
cal immunofluorescence as described below.
2.5 Immunostaining and confocal
microscopy of cardiac tissue and cultured
cells
Mock, PAmut-, and PB2mut-infected HL-1 cells were collected at speci-
fied hours post-infection (hpi), fixed with methanol for 20 min at -20C
and stored in phosphate-buffered saline. Cells were incubated with a pri-
mary rabbit anti-NP antibody19 and subsequently incubated with a sec-
ondary Alexa 594-conjugated goat anti-rabbit antibody (Molecular
Probes, Eugene, Oregon).
Mock, PAmut-, and PB2mut-infected mouse hearts were collected,
fixed in 15% formalin, and embedded in paraffin [for wild-type (WT)
hearts] or optimum cutting temperature compound (for Cx40eGFP
hearts). About 8- to 10 mm slices were obtained using a microtome.
Prior to use, paraffin samples were deparaffinized and hydrated.
Epitope unmasking was performed using DAKO target retrieval solu-
tion (Ref. S1699) in a PTlink equipment (DAKO). The samples were
used for confocal microscopy using DAPI, and the following primary
antibodies: rabbit anti-NP, rat anti-NP,24 and rabbit anti-laminin
(polyclonal; Sigma); and secondary antibodies: chicken anti-rat AF647
and goat anti-rabbit AF488/AF546 (Molecular Probes, Eugen,
Oregon).AQ7 All images were obtained using an SPE confocal mi-
croscope (Leica). The NPþ area was calculated using a threshold
based on absolute intensity and automatic quantification with FIJI
(National Institutes of Health, USA).
2.6 Histopathology analysis
Ventricular cross-sections from both WT and Cx40eGFP mice were
dehydrated and cut into 10-mm thick sections. Haematoxylin and eosin
(H&E) stained sections were digitized using a NanoZoomer S360 Digital
slide scanner (Hamamatsu, Japan) for subsequent analysis. Sequential
analysis of stained samples was performed to identify any regions with
overt conventional histopathologic features of coagulative necrosis, in-
cluding elongated and pyknotic nuclei, loss of the striated cardiomyocyte
structure, slight increases in colour intensity, and glassy cytoplasm.25
Tissue slices were also stained with Masson Trichrome and digitized
using a NanoZoomer S360 Digital slide scanner (Hamamatsu, Japan) for
analysis. A total of five randomly selected 20 insets per slide were ana-
lysed. Interstitial fibrosis was quantified using ImageJ. Colour threshold
hue (scale: 0–255) was adjusted for each image to include only blue pix-
els (scale: 115–210), corresponding to collagen fibres, and the values for
each area were recorded. Fibrosis proportion (blue staining areas/total
tissue area) was measured in every inset and a mean value was assigned
to each sample.
2.7 ATP quantification
ATP content was assessed by ATP Bioluminescence Assay Kit CLS II
(Roche, Mannheim, Germany) according to the manufacturer’s
instructions.











































2.8 3D reconstructions of viral protein in
cardiac tissue
3D localization of viral particles was performed using the Imaris
Software (Bitplane AG, Switzerland). For 3D reconstructions, we used a
0.20-mm detail level and a threshold based on absolute intensity. All
images were reconstructed from a 5–10mm depth stacked image.
2.9 RNA extraction and PCR
RNA was isolated from myocardial samples of Mock, PAmut-, and
PB2mut-infected mouse hearts using TRIzol (15596026, Thermo Fisher
Scientific). cDNA was then synthesized from total RNA using the
Applied Biosystems High Capacity cDNA Reverse Transcription kit
(4368814, Thermo Fisher Scientific). Gene expression analysis in cardiac
tissue was performed by quantitative PCR (qPCR). Then qPCR was con-
ducted with SYBR Green (4367659, Thermo Fisher Scientific), and
cDNA was amplified using DNA primers designed for every gen based
on the mouse genome. Gene expression of interleukin (IL)-1ß, IL-6, lysyl
oxidase, and brain natriuretic peptide were evaluated. Housekeeping
genes (GAPDH and B2M) were measured for gene expression normali-
zation and the 2-DDCt method was used for relative gene expression
quantification.
Specific primers to amplify viral NEP mRNA were designed to detect
it by PCR. NEP mRNA is a spliced mRNA transcribed from the NS viral
segment that is only present in cells with ongoing viral replication and
transcription.26
2.10 Surface ECG analysis of mice infected
with influenza virus
Three groups of WT conscious mice including 10 animals per group
(Mock, PB2mut, and PAmut) were used to study any potential ECG
alterations during sequential follow-up (Figure 1). ECGs were recorded
in the fully awake state to circumvent any potential anaesthesia-related
confounding factor associated with ventilation problems. Upon inocula-
tion (Day 0), ECG changes in conventional intervals (PR segment, QRS
complex, and QT interval) were monitored daily. Three animals were
euthanized on Day 1 after inoculation, two animals on Day 2, and two
Figure 1 Flowchart showing all the experimental sets. C-MRI, cardiac magnetic resonance imaging; dpi, days post-infection; ECG, electrocardiogram;
FA, formaldehyde treatment; hpi, hours post-infection; LV, left ventricle; n, number of inoculated animals; N, total number of animals in each experimental
set; n, number of animals in each group; PFU, plaque-forming units; RV, right ventricle.








































































































animals on Day 4 to obtain ventricular samples for monitoring viral titre,
western-blot, immunohistochemistry, and qPCR analyses. The remaining
three animals per group at Day 4 after inoculation were used for cardiac
magnetic resonance imaging (C-MRI) studies after completing the se-
quential follow-up of ECG parameters. Data were stored for off-line
analysis using custom MatLab scripts for pre-processing, visualization,
and quantification of electrophysiological intervals and heart rate variabil-
ity (see Supplementary material online, Figure S1). Further technical
details are described in the Supplementary material online.
2.11 High-resolution cardiac magnetic
resonance imaging
Nine explanted mouse hearts underwent C-MRI characterization of any
overt and virus-related short-term structural damage. Four days after vi-
rus inoculation, three animals from each experimental group were eu-
thanized after completing the last ECG follow-up (Figure 1). Five minutes
before euthanasia and heart removal, a 0.2 mM/kg bolus of gadolinium-
based contrast agent (Gadovist, Bayer Hispania, S.L.) was injected intra-
venously to ensure that gadolinium reached the whole heart. All
explanted and preserved hearts underwent C-MRI using a 7-T Agilent/
Varian scanner (Agilent, Santa Clara, CA, USA) equipped with a DD2
console and an actively shielded 115/60 gradient with a homemade sole-
noidal small coil for microimaging. The imaging protocol consisted of a
3D image (spin echo sequence, voxel resolution 31.370.331.3mm)
followed by a T1 map (inversion recovery spin echo multi-slice se-
quence, six slices, slice thickness: 0.5 mm). Further technical details are
described in the Supplementary material online, Figures S2–S4.
2.12 Statistical analyses
Student’s t-test, two-way ANOVA, v2, or the non-parametric Kruskal–
Wallis test for multiple comparisons were applied as appropriate. A
P < 0.05 was considered statistically significant. All data were analysed
with GraphPad Prims v.5.00 (GraphPad Software Inc., CA, USA).
3. Results
3.1 Mice infected with influenza virus die
prematurely
We previously identified a higher mortality rate for PAmut virus com-
pared to PB2mut, CAL, and double mutant PB2/PAmut recombinant vi-
ruses.17 During the determination of the 50% lethal dose (infection with
103, 104, 105, 106 pfu) of these recombinant viruses, we observed that
mortality of mice infected with PAmut and PB2/PAmut (dose 106 pfu)
occurred before reaching 75% of the original body weight that consti-
tutes the ethical limit established for euthanasia (range: 95–77% of the
original weight; Figure 2A). The data indicate that these recombinant vi-
ruses may cause premature death in some infected animals.
3.2 Human recombinant viruses are
present in the hearts of infected mice
Mice infected with a previously described F-IAV virus, associated with a
fatal case infection, showed certain amount of infectious particles in their
heart.27 These data, together with premature death documented in
PAmut and PB2/PAmut-infected mice, prompted us to study the ability
of human influenza virus to infect the heart. We explored the presence
of IAV in hearts of mice infected with a sub-lethal dose (103 pfu) of mu-
tant virus and tested for heart viral titres compared with lung viral titres
in each infected animal. At 2 dpi, we found viral particles in the heart of a
high proportion of all infected mice (Figure 2B), but the frequency and
duration of infection were higher in PAmut-infected mice. Lung viral
titres progressively increased after inoculation in all infected mice and
reached the highest values at 2 dpi (Figure 2C). Lung viral titres also
showed that mice infected with PAmut or PB2/PAmut had the highest vi-
ral titres at all time intervals.17 Accordingly, cardiac viral titres were
detected earlier in PAmut-infected mice (Figure 2C) and remained for
longer time during the 4-day follow-up period. Importantly, lung viral
titres obtained with any of the recombinant viruses did not statistically
correlate with viral titres in the mouse heart at any of the time intervals
(Figure 2C, shown r2). Thus, similar lung viral titres showed a wide range
of heart viral titres (in Figure 2C, see red and orange dots at 2 dpi and
black and red dots at 4 dpi). The latter supports the notion that heart in-
fection does not directly correlate with the extension of lung infection,
and virus pathogenicity may be a more relevant factor to reach and infect
the heart in vivo.
3.3 Influenza virus replication is present in
infected hearts
The spliced viral NEP mRNA (a product of replication, Figure 2D–G) was
detected in all infected hearts (‘þ’ samples in Figure 2F) and was absent in
heart samples of infected animals without heart infection (‘-’ samples in
Figure 2F). Furthermore, the viral NP protein was found in the nucleus
and cytoplasm of cardiomyocytes from infected hearts (Figure 3A and B
and see Supplementary material online, Figure S5 and Videos S1 and S2).
Moreover, quantification of the NP signal in infected ventricular tissue
showed significantly higher values in PAmut-infected hearts compared
with PB2- and Mock-infected hearts (Figure 3C). This is consistent with
higher viral titres in PAmut-infected hearts (Figure 2C). Further analysis of
infected hearts also detected NP signal in cardiac endothelial cells
(Figure 3D). These data demonstrate that human IAV can replicate in the
heart of infected mice. Furthermore, virus pathogenicity and infection of
the endothelial cells of blood vessels seem to be involved in viral spread
from lung tissue to the heart.
3.4 Viral pathogenicity determines viral
replication kinetics in cardiac cells
Direct cardiac pathogenicity and replication, independent of lung infec-
tion, was addressed using infected mouse HL-1 cardiac muscle cells with
PAmut or PB2mut recombinants; or with CAL recombinant as control
virus. Infection at low moi (0.001) showed significantly faster-growing ki-
netics and higher viral titres in PAmut-infected cells compared to
PB2mut- or CAL-infected cells (Figure 3E). Interestingly, such differences
were not present in lung epithelial cells infected with either PAmut or
PB2mut virus (see Supplementary material online, Figure S6).17 Cells
were also infected at high moi (3) with PAmut or PB2mut viruses, or
were Mock-infected as control. PAmut-infected cells accumulated signifi-
cantly higher levels of viral NP and PB1 proteins than attenuated
PB2mut-infected cells (see Supplementary material online, Figure S7).
Differences in viral kinetics were also monitored by nuclear (early infec-
tion) or cytoplasmic (late infection) localization of NP in cells infected at
5 moi using confocal immunofluorescence microscopy (Figure 3F). At 8
hpi, NP was mainly detected in the nucleus of PB2mut-infected cells and
in the cytoplasm of PAmut-infected cells. Quantitative analysis showed
that NP distribution was significantly different between PB2mut and
PAmut viruses (Figure 3G). Altogether, the data demonstrate that human
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Figure 2 Premature death upon influenza A virus (IAV) infection correlates with high levels of infectious particles, active viral replication, and the presence
of spliced viral NEP mRNA in the heart. BALB/c AnNHsd mice (n = 4) were intranasally infected with 106 pfu of the indicated viruses. (A) Body weights rep-
resented as percentage of body weight at inoculation (time 0). Red numbers denote body weight of animals with premature death. The experiment was per-
formed twice and the results were similar. (B) BALB/c AnNHsd mice (n = 5) were intranasally infected with 103 pfu with the indicated viruses. Prevalence of
IAV in the heart of infected animals shown as percentage of total animals. (C) Correlation of heart viral titres in each IAV-infected mouse with lung viral titres
at different days post-infection (dpi). NA, not applicable, all values below detection limit in the heart. (D) Scheme of influenza virus spliced NEP mRNA and
NS1 mRNA collinear to full-length NS segment. Red and green arrows indicate localization of primers used in PCR to detect NEP mRNA. (E) Sequence of
the spliced NEP mRNA sequence (grey) within the full-length viral NS segment sequence. Red and green rectangles represent the sequence of forward and



























































































IAV can infect and replicate in cardiac cells with replication kinetics di-
rectly related to virus pathogenicity.
3.5 Viral pathogenicity determines early
inflammation and imbalance in
extracellular matrix of infected hearts
Heart samples from PAmut-, PB2mut-, and control Mock-infected mice
did not reveal any overt acute histopathologic alterations in H&E stained
samples (Figure 4A). Masson Trichrome staining of heart tissue did not re-
veal any significant increase in cardiac fibrosis with any of the recombi-
nant viruses at 4 days after inoculation (Figure 4B and C). Consistent with
histopathology analyses, neither post-contrast T1 mapping data nor the
normalized fibrosis volumes was significantly different among Mock-,
PB2mut-, and PAmut-infected mice (see Supplementary material online,
Table S2). Cardiac MRI-derived myocardial mass quantification was simi-
lar in infected and Mock control animals. Representative sample cases
are shown in Figures S3 and S4, see Supplementary material online.
More specific analyses using qPCR revealed an early and statistically
significant increase of lysyl oxidase mRNA in cardiac samples from mice
infected with the highly pathogenic PAmut virus (Figure 4D). Although se-
quential echocardiography studies were not performed because of bio-
safety restrictions, Brain Natriuretic Peptide (BNP) mRNA did not
significantly increase in any of the infected groups of animals (Figure 4E).
Conversely, an acute pro-inflammatory response was detected in the
heart of PAmut- and PB2-infected mice. More specifically, IL-1ß mRNA
levels significantly increased in PAmut- and PB2-infected mice compared
to Mock-infected controls (Figure 4F). IL-6 mRNA only increased signifi-
cantly in mice infected with the most pathogenic PAmut virus
(Figure 4G).
3.6 Influenza virus-infected mice show sig-
nificant cardiac conduction alterations
Mice were infected with 106 pfu (dose associated with premature death
in PAmut-infected animals; Figure 2A). A total of 51 820 heartbeats were
included for analysis using an average of 460 ± 92 beats per ECG acquisi-
tion during the 4-day sequential follow-up. PAmut- and PB2mut-infected
mice developed progressively longer RR intervals than controls
(Figure 5A and B). The maximum effect of PAmut and PB2mut infection
on RR intervals was observed at 2 dpi (Figure 5B). PAmut-infected mice
also showed significantly longer RR intervals than PB2mut-infected mice
at 2 dpi (Figure 5B). The PR interval also showed significantly longer val-
ues in PAmut- and PB2mut-infected mice at 2 dpi compared to baseline
values (Figure 5C). QRS complex duration was significantly prolonged in
PAmut-infected mice compared to controls at 2 dpi (Figure 5D).
Corrected QT intervals were similar among groups (Figure 5E). Parallel
to ECG alterations (see Supplementary material online, Table S1) and in-
dicative of disease, body weight loss was substantially higher in PAmut-
and PB2mut-infected mice compared to controls (see Supplementary
material online, Figure S8A). Mortality rates were also significantly higher
in PAmut-infected mice compared to PB2mut-infected animals and con-
trols (see Supplementary material online, Figure S8B). In the same ani-
mals, further molecular analyses showed that ATP levels in PAmut-
infected mice significantly decreased compared to Mock- and PB2mut-
infected mice (Figure 5F). Moreover, decreased ATP levels inversely cor-
related with viral titres in heart samples of those animals (Figure 5G),
which further reflects the higher pathogenicity of the recombinant
PAmut virus. Daily ECG recordings demonstrated that severe cardiac
conduction alterations could be present at the time of premature death.
This may happen in the absence of histopathologic features of coagula-
tive necrosis or a significant increase in fibrosis, as shown in the repre-
sentative case of Figure 5H.
3.7 Infected animals show active viral
replication in cardiac Purkinje cells
Influenza virus infection of cardiac-specific Purkinje cells may further con-
tribute to ECG alterations in vivo. Immunofluorescence and confocal mi-
croscopy analyses in excised hearts (see Supplementary material online,
Figure S9) from PAmut- and PB2mut-infected Cx40eGFP transgenic mice
identified the NP protein in both the cytoplasm and the nucleus of
Purkinje cells (Figure 6A and see Supplementary material online, Videos S3
and S4). This indicates also active viral replication in the cardiac-specific
conduction system. As reported in infected WT animals, histopathology
analysis did not show overt relevant alterations in H&E and Masson
Trichrome (n = 3 per group, median fibrosis: 0.03%, 0.04%, and 0.01%
for Mock-, PB2mut- and PAmut-infected animals, respectively) stained
samples (Figure 6B and C).
3.8 Human-induced pluripotent stem
cell-derived cardiomyocytes as a model for
human heart infection
Consistent with the data obtained in HL-1 cardiac cells and in the mouse
heart, hiPSC-CMs were also susceptible to human IAV infection. At 12
hpi, after 3 moi infection, viral PB1 accumulation levels were significantly
higher in PAmut-infected cells than in attenuated PB2mut-infected ones
(Figure 7A and B). Moreover, YMLE1 protease, an indicator of mitochon-
drial integrity,28,29 significantly decreased in infected cells. The latter was
also more exacerbated in PAmut-infected cells compared to PB2mut-
infected ones (Figure 7C and D). This was also consistent with the de-
crease in ATP levels documented in infected mice hearts (Figure 5F).
Further analysis of the underlying causes associated with the electro-
physiological phenotype in vivo showed that Kir2.1 levels did not signifi-
cantly change among the infected groups (Figure 7E and F), consistent
with non-significant changes in the QT interval in vivo (Figure 5E).
Conversely, Cx43 and NaV1.5 levels decreased in influenza virus-
infected cells, especially in the highly pathogenic PAmut infection
(Figure 7E, G, and H), which was also consistent with QRS complex pro-
longation in vivo (Figure 5D).
Figure 2 Continued
reverse primers used for amplification of spliced NEP mRNA, respectively. (F) Agarose gel with amplified NEP mRNA in heart samples of CAL-,
PB2mut-, PAmut-, or PB2/PAmut-infected mice obtained at 2 dpi (at time of the highest viral titres in panel D). þ indicates samples showing infec-
tious viral particles. - indicates samples not showing infectious viral particles as determined by plaque assay (B and C). Arrow bands corresponding
to spliced NEP mRNA. The asterisk indicates dimer primers. (G) Sequence of the obtained amplicons.
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Figure 3 Active replication of influenza A virus in cardiac tissue. PAmut virus replicates faster than attenuated PB2mut virus in HL-1 cells. (A) Detection of
viral nucleoprotein (NP) by confocal microscopy of immunofluorescences in heart tissue from control animals (MOCK; upper panels, a–d), PAmut virus-
(middle panels, e–i) or PB2mut virus- (lower panels, j–n) infected animals. The boxed areas in merged images (h and m) are shown enlarged in the insets (i
and n). (B) 3D reconstructions of cytoplasmic (left panel) or nuclear (right panel) NP viral protein in PAmut-infected heart tissue (see Supplementary mate-
rial online, Videos S1 and S2). Magenta, auto-fluorescence in cardiomyocytes; NP viral protein is showed in white for better visualization in 3D reconstruc-
tions. (C) Quantification of NP signal in infected heart tissues at 2-day post-infection (dpi). A minimum of 27 images from two different hearts have been
quantified for each group. *P < 0.05 by Student’s t-test. (D) Detection of viral NP in endothelial cells surrounding a heart blood vessel from animals infected
with PAmut virus. (E) Viral replication kinetics of control CAL, PAmut, or PB2mut virus in cultured HL-1-infected cells (10-3 multiplicity of infection, moi).
Experiments were performed in triplicates. Significance was determined by two-way ANOVA with Bonferroni post hoc test (*P < 0.05; **P < 0.01;
































We report that both pathogenic and attenuated human IAVs can infect
cardiomyocytes and Purkinje cells in the mouse heart without correla-
tion with lung viral titres. The infection was also present in cardiac endo-
thelial cells, which represent a potential pathway for viral transmission
from lung to heart tissue. The highly pathogenic recombinant PAmut vi-
rus replicates more rapidly in mouse cardiomyocyte cultures and indu-
ces an early increase in inflammatory cytokines with overt signs of
bradycardia and abnormal cardiac impulse propagation in vivo that may
lead to premature death. The electrophysiological phenotype in vivo was
associated with an acute decrease in Cx43 and NaV1.5 levels, and overt
mitochondrial dysfunction in infected hiPSC-CMs. The results indicate
that direct heart infection may have important implications in human in-
fluenza virus outbreaks, in addition to the indirect effects derived from
respiratory pathology. The latter is consistent with clinical reports of se-
vere cardiac complications in infected patients, even without apparent
respiratory damage.13,14
Multiple reports have indicated a temporal relationship of influenza
outbreaks with acute coronary events and increased mortality in the el-
derly.3,30,31 Recently, Kwong et al.32 have documented an increased inci-
dence of acute myocardial infarction within 7 days after detection of IAV
Figure 3 Continued
***P < 0.001). (F) At indicated hours post-infection (hpi), samples of Mock-, PB2mut- or PAmut-infected HL-1 cells (moi 5) were used for immuno-
fluorescence confocal microscopy. Arrows and arrowheads indicate nuclear and cytoplasmic localization of NP protein, respectively. Experiments
were performed in triplicates. (G) Distribution of nuclear, cytoplasmic, or both localizations of NP viral protein within 100% of positive PB2mut- or
PAmut-infected cells at 8 hpi (top) and 12 hpi (bottom). A minimum of 160 cells from three independent experiments were analysed for PB2mut
or PAmut virus at each time point. Significance was determined by v2 test (*** P < 0.001). Blue, nucleus staining (DAPI); green, laminin; red, NP viral
protein (but white, C).
Figure 4 Histopathology and tissue changes in infected mice. (A) Representative heart samples of H&E staining in the three groups of infected mice. (B)
Representative heart samples of Masson Trichrome staining from the three groups of infected mice. (C) Fibrosis quantification in heart samples obtained
4 days after infection (n = 3). (D–G) mRNA quantification and statistical comparisons of lysil oxidase (LOX) (D), BNP (E), IL-1ß (F), and IL-6 (G) among
Mock (n = 4), PA mut (n = 6) and PB2mut (n = 7) groups of infected mice. Significance was determined by two-way ANOVA (*P < 0.05; **P < 0.01). BNP,
brain natriuretic peptide.






















infection. In fact, during influenza epidemics, people with cardiovascular
disease are particularly at risk of events, and annual influenza virus immu-
nization is currently recommended in adults with cardiovascular dis-
ease.33 Moreover, clinical evidence indicates that influenza vaccination
may protect against acute myocardial infarction.34,35
Despite the association between influenza virus infection and cardio-
vascular events, influenza virus antigens or RNAs have only rarely been
noticed in the myocardium. Viral RNA was detected in a myocardial bi-
opsy of a young woman with fulminant myocarditis and cardiogenic
shock.36 Viral antigens have been also detected in cardiomyocytes from
Figure 5 ECG alterations in mice infected with influenza virus. (A) Randomly selected tracings from control, PB2mut, and PAmut mice at Days 0 and 2
after virus inoculation. The tracings show overt prolongation of RR intervals (slower heart rate) and PR intervals in PAmut-infected mice at Day 2. Blue
asterisks indicate R waves. (B–E) Surface ECG-based quantification of cardiac rhythm and conduction alterations in virus-infected animals and control
mice. *, #, †, and ‡ show P < 0.05 for PAmut vs. PAmut Day0 (*), PB2mut vs. PB2mut Day0 (#), PAmut vs. controls at that time point (†), and PB2mut vs.
controls at that time point (‡). Animals (n = 10) were intranasally infected with 106 pfu of PB2mut, or PAmut recombinant virus or were Mock-infected,
and were sequentially euthanized for collection of samples . Number of animals for comparisons: Days 0, 1: n = 10 (PB2 and PA) and n = 9 (Mock. The
10th animal was excluded due to poor signal quality); Day 2: n = 7 per group; Day 3: n = 5 per group; and Day 4: n = 5 (PB2, Mock) and n = 4 (PA. The fifth
animal died on Day 3). Significance was determined by two-way repeated-measures ANOVA with Bonferroni post hoc test (*P < 0.05; **P < 0.01). (F)
ATP levels were evaluated in triplicates in total heart extracts at 1- (n = 3), 2- (n = 2), and 4- (n = 2) day post-infection (dpi). Mock data are shown as
100% in one dot. (G) Viral titres were determined in hearts of the same infected animals at indicated dpi and were evaluated in duplicates (1 dpi, n = 3;
2 dpi, n = 2; 4 dpi, n = 2, per group). In (F) and (G), significance was determined by Student’s t-test (ns: not significant, *P < 0.05, **P < 0.01). (H)
Representative ECG alterations in a PAmut-infected mouse before dead. Haematoxylin and eosin (H&E) and Masson trichrome staining from the same
animal.






















..another patient with fulminant myocarditis.14 Endomyocardial biopsies
in a large series of patients with myocarditis have identified IAV RNA in
five patients.37 These clinical data and more dramatic reports describing
the association between IAV infection and sudden cardiac death suggest
that rather than a non-pathogenic viral RNA detection, concomitant to
pulmonary infection, IAV identification in the myocardium may represent
a highly pathogenic scenario that may determine clinical out-
comes.13,15,38 A recent report by Kenney et al.39 have shown that influ-
enza virus replication in the heart and virus-related mortality
dramatically increased in knockout mice with antiviral restriction factor
IFN-induced transmembrane protein 3 (IFITM3) deficiency. These
authors used a mouse-adapted influenza virus strain that caused cardiac
Figure 6 Active replication of influenza A virus in Purkinje cells. (A) Detection of the NP viral protein using immunofluorescence confocal microscopy
in heart tissue from Cx40eGFP MOCK-infected mice (upper panels, a–c) and animals infected with 106 pfu of either PAmut virus (middle panels, d–f) or
PB2mut virus (lower panels, g–i). Right panels (j–k) show 3D reconstructions of the NP viral protein in Purkinje cells of PAmut- (j) or PB2mut-infected
hearts (k) from Cx40eGFP animals (see also Supplementary material online, Videos S3 and S4). Blue, nuclear staining (DAPI); green, GFP; red, laminin; white,
NP viral protein staining. (B and C) H&E staining (B) and Masson Trichrome staining (C) of representative heart samples from Cx40eGFP-infected mice.








































































































rhythm alterations and early activation of profibrotic and inflammatory
pathways. Our results provide new evidence of IAV virus replication in
heart tissue using human recombinant viruses carrying highly pathogenic
(PAmut) and attenuated (PB2mut) mutations present in a virus isolated
from a fatal-patient case infected during the 2009 pandemic.17
Moreover, our data show that heart infection and viral titres do not cor-
relate with lung viral titres, which supports the notion that rather than a
consequence of respiratory damage, cardiac complications may also re-
late to virus pathogenicity and independent replication in the myocar-
dium and specific cardiac conduction systems.
The higher pathogenicity of the recombinant PAmut virus may be re-
lated to the fact that this virus accumulates low amounts of defective vi-
ral genomes, which induces a lower antiviral response in cultured cells
and a higher lung inflammation compared with the PB2mut.17
Interestingly, such a reduced activation of the antiviral state might imply a
delay in the immune response of infected animals, which may enable the
virus to grow and disseminate uncontrolled for a short time, sufficient to
infect the heart tissue. Consistent with such a hypothesis, we found in-
fectious particles in 100% of the hearts from PAmut-infected mice at
1 dpi (Figure 2B). The deficiency in the antiviral restriction factor IFITM3,
recently associated with enhanced pathogenesis and viral replication in
the heart of infected mice,39 reinforce the antiviral response-related
pathogenicity of the PAmut virus. Moreover, the recombinant PAmut vi-
rus replicated faster than the PB2mut in cardiac cultured cells, and gener-
ated larger ECG alterations and acute mitochondrial dysfunction
compared with the attenuated PB2mut. Altogether the data indicate that
the specific PA D529N mutation, present in a human fatal case virus,
provides an advantage for virus dissemination and replication in the myo-
cardium. Therefore, it seems reasonable that, rather than being an indi-
rect consequence of respiratory damage upon infection with highly
pathogenic IAVs, a delay in the early immune response facilitates direct
cardiac infection and early myocardial damage.
Possible explanations for the scarce detection of viral determinants in
cardiac tissue of infected patients could be a low capability of the major-
ity of influenza virus strains to infect cardiac cells and/or low levels of vi-
ral replication in heart tissue. Upregulation of specific proteases capable
of cleaving influenza virus HA in the mouse heart and in H9c2 rat cardio-
myocytes has been associated with the capacity of IAVs to propagate in
the heart.40 Here, we demonstrate the ability of human H1N1 IAV to in-
fect and replicate in heart tissue of infected mice, HL-1 cardiac cells and
hiPSC-CMs. Although all the tested recombinant viruses infected the
heart (Figure 2), including the attenuated virus PB2mut, differences in
pathogenicity correlated with cardiac virus infection capacity and replica-
tion. ECG alterations and underlying molecular changes (Figures 5 and 7)
were also consistent with virus pathogenicity. Interestingly, IAV infection
of HL-1 cells showed significantly faster-growing kinetics and higher viral
titres in PAmut-infected cells compared to PB2mut- or control WT
CAL-infected cells. However, such differences were not present in lung
epithelial cells (see Supplementary material online, Figure S6), which high-
lights the relevance of virus pathogenicity to replicate in cardiac tissue.
The in vivo mouse electrophysiological phenotype showed that
PAmut- and PB2mut-infected mice developed acute progressive brady-
cardia. Bradycardia has been also reported by Kenney et al.39 using a
mouse-adapted influenza virus strain. Here, we also report that the most
pathogenic strain (i.e. PAmut) significantly affected the PR interval and
QRS complex duration. Interestingly, conduction abnormalities and
high-degree atrio-ventricular block have been documented also in hu-
man cases of myocarditis associated with influenza A virus infection.14 In
addition, and early inflammatory state was also present in the heart of
infected mice. Moreover, ECG alterations and pro-inflammatory cyto-
kines were consistent with higher viral titres and higher viral replication
in the heart of PAmut-infected mice compared to PB2mut- and Mock-
infected animals. Further molecular studies in infected hiPSC-CMs also
showed consistent alterations in ion channel expression and mitochon-
drial dysfunction, which were more evident in PAmut-infected cells.
Interestingly, YMEL1 has been involved in mitochondria dynamics,28
heart failure,41 maintenance of mitochondrial structure, and respiratory
chain biogenesis, and stresses the relevance of correct proteostasis for
mitochondrial integrity.42 Accordingly, the M2 protein of influenza virus
Figure 7 Influenza A virus replication and electrophysiological phe-
notype of infected hiPSC-CMs. hiPSC-CMs were Mock-infected or
infected with the indicated virus (3 moi) Samples were used to detect
the indicated proteins by western blot at the specified hours post-infec-
tion (hpi). (A) Viral PB1 protein. (C) Mitochondrial protease YMEL1. (E)
Kir2.1 and NaV1.5 ion channels and Connexin43. GAPDH or a-actinin
were used as loading control and healthy human ventricle tissue (H—
ventricle) was loaded as human ion channels and Connexin43 control.
MW denotes molecular weight markers. The experiment was per-
formed in triplicates (duplicates for YMEL1); one representative sample
is shown. Mock data are shown as 100% in one dot. B, D, F, G, and H in-
dicate protein quantification and statistically significant analysis
(*P < 0.05, **P < 0.01, ***P < 0.001 by the Student’s t-test). moi, multi-
plicity of infection.








































































































(a viroprotein) causes alteration of mitochondrial morphology, dissipa-
tion of mitochondrial membrane potential, and cell death43 (reviewed in
Refs44,45). Altogether, the data support a heart mitochondrial damage
observed upon human IAV infection (Figure 7C and D), consistently with
ATP decrease, especially in the highly pathogenic PAmut virus
(Figure 5F).
In the clinic, ventricular arrhythmia leading to sudden cardiac death
may be also a fatal consequence of fulminant myocarditis associated with
influenza A infection.13 In mice, we have not documented ventricular ar-
rhythmic events in any of the infected groups of mice. Conversely, we
have documented severe bradycardia and conduction abnormalities in
one PAmut-infected mouse at the time of premature death 3 days after
infection. However, myocarditis-related ventricular arrhythmia is a rare
phenomenon in infected patients, which may also be the case in mice. In
addition, we did not have the possibility of obtaining continuous ECG
recordings under biosafety level 2þ conditions, which has also affected
our ability to record ventricular arrhythmia. Notwithstanding such differ-
ent rhythm alterations reported in the clinic, the ability of the virus to in-
fect cardiac tissue makes it a potential hazard.13–15,38 Here, we report
that this is especially relevant for viral strains of high pathogenicity.
Fortunately, there are clinical reports of influenza-induced fulminant
myocarditis successfully treated with intravenous peramivir.46,47
Therefore, new studies are warranted to investigate the potential value
of antiviral therapies in cases with heart infection in the clinic.
4.1 Limitations
Biosafety restrictions did not allow performing echocardiography studies
in mice undergoing sequential ECG monitoring. Histopathology analysis
did not show immune cell infiltration at 4-day post-infection, which may
be consistent with sequential findings of viral myocarditis in mice models;
with an initial increase in inflammatory cytokines prior to inflammatory
cell infiltration that would be predominantly evident at day 5 post-
infection.48
5. Conclusions
Human IAV can infect the heart and cardiac-specific conduction system,
which may contribute to virus-related cardiac complications and prema-
ture death in the clinic.
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Translational perspective
Influenza A virus (IAV) can infect several cell types in the mouse heart. Human IAV with the highest pathogenicity replicate more rapidly in mouse
cardiomyocyte cultures and induce a cardiac pro-inflammatory state, which correlates with underlying molecular changes and mitochondrial dysfunc-
tion in human-induced pluripotent stem cell-derived cardiomyocytes. The data demonstrate that heart infection and associated damage need not be
a consequence of lung pathology. In fact, direct cardiac pathogenicity with the virus reaching and infecting the heart seems more relevant, which sup-
ports the relevance of early detection of IAV in clinical cases with acute cardiac disease during influenza outbreaks.
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